BKBanu Kaymak

Banu Kaymak

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Banu Kaymak has a total of 13 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Familiarity with neurodiversity and its association with autism conceptualization and stigma among medical and psychology students in Türkiye

    by Banu Kaymak, Rahime Duygu Temeltürk, Merve Cikili Uytun, Yağmur Özgür Karabıyıkoğlu, Sıla Kutlar Kapici, Rabia Enis, Nilüfer Yildiz Kismet, Didem Behice Öztop

  • Open Access

    Prevalence, Phenotypic Correlates and Predictive Factors of Catatonia in Adolescents With Autism Spectrum Disorder

    by Rahime Duygu Temelturk, Esra Yurumez, Banu Kaymak, Yağmur Özgür Karabıyıkıoglu, Nisa Didem Zengın, Didem Behice Öztop

    Background: Catatonia, a psychomotor syndrome increasingly recognized in individuals with autism spectrum disorder (ASD), remains frequently underdiagnosed due to symptom overlap, particularly in adolescent populations where data remain limited. This study aimed to determine the prevalence, clinical correlates and predictive factors of catatonia in adolescents with ASD, focusing on sociodemographic, behavioural and affective characteristics. Methods: A total of 107 adolescents aged 12–20 years with ASD were evaluated at a tertiary child and adolescent psychiatry outpatient clinic. The diagnosis of catatonia was established using DSM‐5 criteria and the Bush–Francis Catatonia Rating Scale (BFCRS). ASD severity, repetitive behaviours and internalizing symptoms were assessed using the Global Assessment Scale, the Autism Behaviour Checklist (ABC), the Repetitive Behaviour Scale–Revised (RBS‐R) and the Revised Child Anxiety and Depression Scale–Parent version (RCADS‐P). Group comparisons, correlation analyses and binary logistic regression were performed. Results: Catatonia was identified in 21.5% of participants. The most frequent symptoms were stereotypy (73.8%), impulsivity (37.4%), echolalia (36.4%), verbigeration (30.8%) and agitation/excitement (30.8%). Female sex, greater ASD severity, depressive symptoms and separation anxiety were significantly associated with catatonia. The catatonia group demonstrated higher scores on the ABC‐Relationship Building, RBS‐R‐Stereotyped Behaviour and RCADS‐P‐Depression subscales. Logistic regression revealed that female gender and clinically significant separation anxiety symptoms were independent predictors of catatonia (Nagelkerke R 2 = 0.26, p < 0.001). Conclusions: These findings highlight the importance of targeted screening for catatonia in ASD populations, particularly in females and individuals with co‐occurring separation anxiety symptoms. Early recognition and intervention may mitigate functional deterioration and improve clinical outcomes.


  • Neuroinflammatory Pathways in Autism Spectrum Disorder: Unraveling the Role of Sirtuin 1 in Clinical Samples

    by Merve Cikili‐Uytun, Esra Yurumez, Banu Kaymak, Ozlem Dogan, Humeyra Hilal Ozturk, Beyza Nur Baysar Kanoglu, Didem Behice Oztop

    Despite extensive research, the etiological factors contributing to autism spectrum disorder (ASD) remain incompletely understood, with potential influences ranging from genetic predispositions to environmental factors. Sirtuin 1 (SIRT1), an NAD + ‐dependent histone deacetylase involved in mitigating oxidative stress and its association with other neurodevelopmental disorders, explores its function in ASD. This study aimed to elucidate the relationship between SIRT1 and inflammatory cytokines, specifically interleukin 6 (IL‐6) and tumor necrosis factor alpha (TNF‐α), in patients with ASD. This study enrolled 46 children diagnosed with ASD and 44 typically developing (TD) children aged 36–120 months. Diagnosis of ASD was confirmed using DSM‐5 criteria through clinical and observational assessments conducted by three experienced child and adolescent psychiatrists at the outpatient Infant Mental Health unit of Ankara University. The Childhood Autism Rating Scale (CARS) and the Repetitive Behavior Scale‐Revised (RBS‐R) were used to assess autistic behaviors. Analysis of serum levels of SIRT1, IL‐6, and TNF‐α revealed no significant differences between the ASD group and the TD group. Correlation analysis demonstrated a significant positive relationship between SIRT1 levels and IL‐6 ( r = 0.71, p < 0.001) and TNF‐α ( r = 0.86, p < 0.001). Additionally, regression phenomena exhibited a moderate negative correlation with IL‐6 ( r = −0.32, p = 0.02) and TNF‐α ( r = −0.38, p = 0.008). Age was positively correlated with levels of IL‐6, TNF‐α, and SIRT1. However, no correlations were found between these parameters and gender. These findings do not support the hypothesized role of disturbances in the expression of circulating cytokines and SIRT1 as indicators of systemic inflammation in autism. Further longitudinal studies should examine these immune markers in blood samples from large sample sizes.


  • Neurodegeneration in Autism: A Study of Clusterin, Very Long-Chain Fatty Acids, and Carnitine

    by Esra Yurumez, Merve Cikili-Uytun, Banu Kaymak, Ozlem Dogan, Humeyra Hilal Ozturk, Beyza Nur Baysar-Kanoglu, Didem Behice Oztop

    The clinical identification of regression phenomena in ASD lacks specific biological or laboratory criteria and is often based on family history and highly subjective observations by clinicians. The present study aimed to investigate the potential role of plasma clusterin (CLU), very long-chain fatty acids (VLCFA), and carnitine as biomarkers of neurodegeneration in children with autism spectrum disorder (ASD) with and without regression. By exploring these biomarkers, we sought to provide insights into mitochondrial dysfunction, glial activation, and lipid metabolism, which may contribute to the pathophysiology of ASD and aid in the early diagnosis and intervention of regression phenomena in ASD. Ninety children aged 2–6 years were included: 30 with autism spectrum disorder (ASD), 30 with regressive ASD, and 30 healthy controls. Psychiatric assessments were conducted using DSM-5 criteria, CARS, ABC, RBS-R, and ASSQ scales. Regression in ASD was evaluated retrospectively using a modified ADI-R questionnaire. Fasting blood samples were collected, and plasma clusterin (CLU), VLCFA, and carnitine levels were measured. Statistical analyses were performed using MANOVA to assess the effect of group differences on dependent biochemical variables. Serum clusterin and carnitine levels showed no significant differences between groups. However, C22 VLCFA levels were significantly higher in both autism groups compared to controls (p = 0.04), with post hoc analysis indicating the difference between the non-regressive and control groups (p = 0.02). Serum carnitine was positively correlated with stereotypic behaviors subscale scores (r = 0.37, p = 0.004) and total scores (r = 0.35, p = 0.006) of RBS-R. Our study provides insights into the complexities of biomarker research in autism spectrum disorder (ASD), highlighting the challenges in identifying consistent biological markers for regression and non-regression phenotypes. Although no significant findings were observed, further biomarker studies are essential to distinguish possible endophenotypes, improve early diagnosis, and uncover potential therapeutic targets in ASD.